Wilson Therapeutics
Stockholm
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases such as Wilson Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a new treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study in Wilson Disease patients.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $68.9M
- Funding stage: M&A
- Last round: Post-IPO Equity (Dec 2017)
- Ticker: sto:WTX
- Website: wilsontherapeutics.com
- Phone: 46 8 796 00 00
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/wilson-therapeutics-2242113 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.